ASEDASCIENCES
LIVE

Serial Number

79130387

Owner

AsedaSciences AG

Attorney

Jeffrey A. Smith

Filing Date

Mar 20, 2013

Add to watchlist:

No watchlists yet
View on USPTO

ASEDASCIENCES Trademark

Serial Number: 79130387 • Registration: 4541102

ASEDASCIENCES is a trademark filed by AsedaSciences AG on March 20, 2013. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

AsedaSciences AG (6 trademarks)

Untere Paulistrasse 6a
Schindellegi CH-8834 , CH

Entity Type: 99

AsedaSciences GmbH (2 trademarks)

Untere Paulistrasse 6a
CH-8834 Schindellegi , CH

Entity Type: 99

Trademark Details

Filing Date

March 20, 2013

Registration Date

June 3, 2014

Published for Opposition

March 18, 2014

Goods & Services

[ Measuring apparatus and instruments, namely, free flow electrophoresis equipment for protein separation and isolation, and flow cytometry analyzers for cellular analysis; scientific, optical, measuring, signaling and checking apparatus and instruments, namely, free flow electrophoresis equipment for protein separation and isolation, and flow cytometers for single cell and population based cellular analysis; measuring and testing machines and instruments, namely, protein separation and isolation instruments, flow cytometers, and laboratory liquid handlers and automation for testing and implementing cellular based screening methods; laboratory apparatus and instruments for use in growing, maintaining, evaluating and quality control of cell cultures, automated liquid dispensing, protein separation and isolation, single cell and population based cellular analysis, and the assessment of compound or drug effects on cellular physiology and biology, not for medical purposes; chemistry apparatus and instruments for maintaining, evaluating and quality control of cell cultures, automated liquid dispensing of compound preparations and chemical reagents, protein separation and isolation, single cell and population based cellular analysis, and the assessment of compound or drug effects on cellular physiology and biology, not for medical purposes ]

[ In vitro diagnostic preparations for medical use; diagnostic test reagents for medical use; chemical reagents for medical or veterinary use; diagnostic reagents and contrast media agents for medical use; Medical diagnostic reagents; Reagents for medical use ]

Scientific research and development; scientific and technological services, namely, novel multi-parametric phenotypic screening in the nature of analytical testing services and protein isolation for the characterization and simultaneous identification of multiple biological and physiological effects caused by drug candidates on live human cell models in the field of pharmaceutical research, drug discovery and characterization of compound effect, and scientific research and development relating thereto; Scientific and technological services for scientific analysis, testing and research in the fields of pharmaceutical research [, drug discovery and characterization of compound effect, and protein separation, isolation and characterization ]; scientific research services; scientific testing and analysis in the fields of pharmaceutical research, drug discovery and characterization of compound effect [, and protein separation, isolation and characterization ]; computer-assisted scientific research, testing and analysis services in the fields of pharmaceutical research, drug discovery and characterization of compound effect by using mathematical and statistical algorithms to compare and predict the effect of a target compound to that of an approved drug or known toxin, where a biological fingerprint is created and analyzed by measuring the broad physiological and biological effect of said compounds on live human cells; laboratory research and analysis services in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds, and protein separation, isolation and characterization; [ pharmaceutical research and development; ] Scientific research and scientific and technological services, namely, analytical testing and phenotypic screening services in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds [, and protein separation, isolation and characterization ]; scientific laboratory services in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds [, and protein separation, isolation and characterization ]; scientific and technological services, namely, analytical testing and phenotypic screening services in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds, and protein separation, isolation and characterization; [ provision of information about medical and scientific research in the field of pharmaceuticals; preparation of reports on scientific research; ] provision of scientific information on technological research in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds; [ provision of scientific information about industrial analysis and research services in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds; provision of information and data relating to medical research and development and veterinary medical research; consultancy services in the field of pharmaceutical research; consultancy relating to research and development in the field of therapeutics; engineering and ] scientific consultancy services in the fields of pharmaceutical research, drug discovery and characterization of chemical compounds [, and protein separation, isolation and characterization; provision of technical advice in the field of scientific and industrial research; consultancy in the field of scientific and industrial research ]

Filing History

PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Feb 14, 2025 INPR
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
Jun 13, 2024 NA71
REGISTERED-SEC.71 ACCEPTED
Jun 13, 2024 71AG
TEAS SECTION 71 RECEIVED
Jun 3, 2024 ES71
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Jun 7, 2023 LIMN
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
Jun 3, 2023 REM4
INTERNATIONAL REGISTRATION RENEWED
Mar 31, 2023 RNWL
LIMITATION OF GOODS RECEIVED FROM IB
Mar 27, 2023 LIMG
PARTIAL INVALIDATION PROCESSED BY THE IB
May 29, 2022 INNP
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Apr 3, 2022 INPS
INVALIDATION PROCESSED
Apr 3, 2022 INPC
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Nov 15, 2021 INPR
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
Mar 15, 2021 NA75
REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.
Mar 15, 2021 C75P
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Feb 1, 2021 APRE
TEAS SECTION 71 & 15 RECEIVED
Dec 3, 2020 ES75
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Jun 3, 2019 REM3
FINAL DECISION TRANSACTION PROCESSED BY IB
Nov 28, 2014 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Oct 27, 2014 FICS
FINAL DISPOSITION PROCESSED
Oct 27, 2014 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Sep 3, 2014 FICR
CHANGE OF NAME/ADDRESS REC'D FROM IB
Jul 31, 2014 ADCH
REGISTERED-PRINCIPAL REGISTER
Jun 3, 2014 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 18, 2014 NPUB
PUBLISHED FOR OPPOSITION
Mar 18, 2014 PUBO
NOTIFICATION PROCESSED BY IB
Mar 14, 2014 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 26, 2014 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Feb 26, 2014 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 26, 2014 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Feb 8, 2014 PREV
ASSIGNED TO LIE
Feb 8, 2014 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 21, 2014 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 18, 2013 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 18, 2013 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 18, 2013 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 18, 2013 CNEA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 2, 2013 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 2, 2013 REAP
REFUSAL PROCESSED BY IB
Jul 22, 2013 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jul 3, 2013 RFCS
REFUSAL PROCESSED BY MPU
Jul 3, 2013 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jul 3, 2013 RFCR
NON-FINAL ACTION WRITTEN
Jul 2, 2013 CNRT
ASSIGNED TO EXAMINER
Jun 28, 2013 DOCK
APPLICATION FILING RECEIPT MAILED
Jun 11, 2013 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 7, 2013 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jun 6, 2013 REPR